Onco Move - Improvement of Psychophysical Fitness in Adult Cancer Survivors

Browse trials for

• Neoplasms 10,818
• Motor Activity 9,798

Keywords

• cancer exercise
• oncology exercise
• physical activity and cancer

Neoplasms

10,818 studies on the registry are indexed under Neoplasms; 2,324 are open to participants now.

This study's planned enrollment of 70 is above the median of 60 across 7,703 interventional studies indexed under Neoplasms.

Lead sponsor

Gdansk University of Physical Education and Sport is the lead sponsor of 37 studies on the registry; 11 are open to participants now.

Study arms

• Experimental
  Intervention Group

  The intervention group will participate in a multicomponent face-to-face Onco Move exercise training programme for 16 weeks. The intervention will include three training sessions per week (each lasting 60 minutes), held in the fitness rooms and the gym at Gdansk University of Physical Education and Sport in Poland. The intervention will include aerobic and strength exercises but also coordination/balance and flexibility, with warm-up and cool-down elements. The assessments will be conducted at four points: before the intervention, after 8 weeks, after 16 weeks, and 3 months after the intervention.

  Other: Onco Move multicomponent face-to-face training program

• No intervention
  Control Group

  The control group will not participate in the exercise training intervention during the course of the project. However, it will take part in all the assessments just like the experimental group: before the intervention, after 8 weeks, after 16 weeks, and 3 months after the intervention. The control group will be allowed to participate in the training intervention after the Onco Move project has ended.

Interventions

• OtherOnco Move multicomponent face-to-face training program

  The Onco Move intervention will include three training sessions per week (each lasting 60 minutes), held in the fitness rooms and the gym at Gdansk University of Physical Education and Sport in Poland for 16 weeks. The intervention will include aerobic and strength exercises but also coordination/balance and flexibility, with warm-up and cool-down elements.

Primary outcomes

1. Assessed changes from baseline Health-Related Quality of Life (HRQOL)

   HRQOL will be assessed pre-, post-intervention, and at follow-up using validated questionnaire: European Organisation for Research and Treatment of Cancer Core Quality of Life questionnaire-Core 30 (EORTC QLQ-C30). This instrument measures general quality of life and includes multiple subscales (e.g. physical, emotional, cognitive functioning). Scores on each scale range from 0 to 100. * For functional scales and global health status, higher scores indicate better functioning or QoL. * For symptom scales/items, higher scores indicate more severe symptoms (i.e. worse outcomes). Data will be collected via digital or paper formats and analyzed. Statistical methods include repeated measures ANOVA and linear mixed-effects models to detect changes over time. Missing data will be handled via multiple imputation. This approach provides a comprehensive assessment of psychological and functional well-being related to the intervention.

   Time frame: From enrolment to 3 months after the intervention

Secondary outcomes

1. Change in female sexual function, assessed by Female Sexual Function Index (FSFI)

   The FSFI is a 19-item validated questionnaire measuring female sexual function across six domains: desire, arousal, lubrication, orgasm, satisfaction, and pain. Scores range from 2 to 36, with higher scores indicating better sexual function. Data collected via digital or paper formats will be analyzed using repeated measures ANOVA and linear mixed-effects models to assess changes over time. Missing data will be addressed with multiple imputation.

   Time frame: From enrolment to 3 months after the intervention

2. Change in male sexual function, assessed by International Index of Erectile Function (IIEF)

   The IIEF is a 15-item questionnaire assessing male sexual function, including erectile function, orgasmic function, sexual desire, intercourse satisfaction, and overall satisfaction. Scores range from 5 to 75, with higher scores indicating better sexual function. Data collected via digital or paper formats will be analyzed using repeated measures ANOVA and linear mixed-effects models to assess changes over time. Missing data will be addressed with multiple imputation.

   Time frame: From enrolment to 3 months after the intervention

3. Change in mood states, assessed by UWIST Mood Adjective Checklist (UMACL)

   UMACL measures three mood dimensions: tense arousal, energetic arousal, and hedonic tone. Scores vary by subscale; higher scores indicate greater presence of the respective mood state. Data collected via digital or paper formats will be analyzed using repeated measures ANOVA and linear mixed-effects models to assess changes over time. Missing data will be addressed with multiple imputation.

   Time frame: From enrolment to 3 months after the intervention

4. Change in perceived stress, assessed by The Feeling of Stress Questionnaire (KPS)

   KPS assesses perceived psychosocial stress across domains such as work and emotional strain. Scores vary by domain; higher scores indicate greater perceived stress. Data collected via digital or paper formats will be analyzed using repeated measures ANOVA and linear mixed-effects models to assess changes over time. Missing data will be addressed with multiple imputation.

   Time frame: From enrolment to 3 months after the intervention

5. Change in anxiety and depression symptoms, assessed by the Four-Item Patient Health Questionnaire For Anxiety And Depression (PHQ-4)

   PHQ-4 is a 4-item screening tool with two items each for anxiety and depression. Scores range from 0 to 12, with higher scores indicating more severe symptoms. Data collected via digital or paper formats will be analyzed using repeated measures ANOVA and linear mixed-effects models to assess changes over time. Missing data will be addressed with multiple imputation.

   Time frame: From enrolment to 3 months after the intervention

6. Change in personality traits, assessed by NEO Five-Factor Inventory (NEO-FFI)

   NEO-FFI assesses five personality traits: Neuroticism, Extraversion, Openness, Agreeableness, and Conscientiousness. Each trait is scored separately; higher scores indicate stronger presence of the trait. Data collected via digital or paper formats will be analyzed using repeated measures ANOVA and linear mixed-effects models to assess changes over time. Missing data will be addressed with multiple imputation.

   Time frame: From enrolment to 3 months after the intervention

7. Change in state and trait anxiety, assessed by State-Trait Anxiety Inventory (STAI)

   STAI includes two 20-item subscales measuring state anxiety (temporary) and trait anxiety (long-term). Scores range from 20 to 80 per subscale, with higher scores indicating greater anxiety. Data collected via digital or paper formats will be analyzed using repeated measures ANOVA and linear mixed-effects models to assess changes over time. Missing data will be addressed with multiple imputation.

   Time frame: From enrolment to 3 months after the intervention

8. Change in lower limb strength, assessed by Chair Stand Test (from Short Physical Performance Battery and Senior Fitness Test)

   Lower limb strength will be measured using the Chair Stand Test, included in both the Short Physical Performance Battery (SPPB) and the Senior Fitness Test (SFT). Participants are asked to rise from a chair without using their arms, either completing five repetitions as fast as possible (SPPB) or as many repetitions as possible in 30 seconds (SFT). Higher scores indicate better lower body strength and functional independence. Data collected via digital or paper formats will be analyzed using repeated measures ANOVA and linear mixed-effects models to assess changes over time. Missing data will be addressed with multiple imputation.

   Time frame: From enrolment to 3 months after the intervention

9. Change in upper limb strength, assessed by Arm Curl Test (from SFT)

   Upper limb strength will be assessed using the Arm Curl Test from the SFT. Participants perform as many bicep curls as possible in 30 seconds using standardized weights (2.3 kg for women and 3.6 kg for men). The number of repetitions is recorded. Higher scores indicate greater upper body muscular strength. Data collected via digital or paper formats will be analyzed using repeated measures ANOVA and linear mixed-effects models to assess changes over time. Missing data will be addressed with multiple imputation.

   Time frame: From enrolment to 3 months after the intervention

10. Change in flexibility, assessed by Toe Touch and Back Scratch Tests (from SFT)

    Flexibility will be assessed using two tests from the Senior Fitness Test (SFT): * The Toe Touch (Sit-and-Reach) Test measures lower body flexibility. * The Back Scratch Test measures upper body (shoulder) flexibility. Reach distances are recorded in centimeters, with positive values indicating the participant reaches beyond the target point. Higher values indicate greater flexibility. Data collected via digital or paper formats will be analyzed using repeated measures ANOVA and linear mixed-effects models to assess changes over time. Missing data will be addressed with multiple imputation.

    Time frame: From enrolment to 3 months after the intervention

11. Change in aerobic capacity, assessed by 6-Minute Walk or 2-Minute Step Test (from SFT)

    Aerobic capacity will be assessed using one of the two tests from the Senior Fitness Test (SFT), selected based on the participant's fitness level: * The 6-Minute Walk Test records the total distance walked in meters. * The 2-Minute Step Test counts the number of knee lifts within 2 minutes. Both tests assess cardiovascular endurance. Higher values represent better aerobic capacity. Data collected via digital or paper formats will be analyzed using repeated measures ANOVA and linear mixed-effects models to assess changes over time. Missing data will be addressed with multiple imputation.

    Time frame: From enrolment to 3 months after the intervention

12. Change in balance and agility, assessed by 8-Foot Up-and-Go Test (from SF)

    Balance and agility will be assessed using the 8-Foot Up-and-Go Test from the Senior Fitness Test (SFT). Participants stand up from a seated position, walk 8 feet (2.44 m), turn, return, and sit down. The time to complete the task is recorded in seconds. Lower times indicate better balance, agility, and risk reduction for falls. Data collected via digital or paper formats will be analyzed using repeated measures ANOVA and linear mixed-effects models to assess changes over time. Missing data will be addressed with multiple imputation.

    Time frame: From enrolment to 3 months after the intervention

13. Change in balance, assessed by Standing Balance Test (from SPPB)

    Static balance will be assessed using the Standing Balance Test from SPPB. Participants are asked to maintain three progressively more challenging foot positions (side-by-side, semi-tandem, tandem) for up to 10 seconds each. The total score ranges from 0 to 4, with higher scores indicating better balance and lower fall risk. Data collected via digital or paper formats will be analyzed using repeated measures ANOVA and linear mixed-effects models to assess changes over time. Missing data will be addressed with multiple imputation.

    Time frame: From enrolment to 3 months after the intervention

14. Change in walking speed, assessed by 4-Meter Walk Test (from SPPB)

    Walking speed will be assessed using the 4-Meter Walk Test from SPPB. Participants walk 4 meters at their usual pace. Time is recorded and speed is calculated in meters per second. Higher speeds indicate better physical function and are associated with reduced fall risk and improved health outcomes. Data collected via digital or paper formats will be analyzed using repeated measures ANOVA and linear mixed-effects models to assess changes over time. Missing data will be addressed with multiple imputation.

    Time frame: From enrolment to 3 months after the intervention

15. Change in pain threshold, assessed by AlgoMed Algometer

    Pain threshold will be evaluated at baseline, post-intervention, and follow-up using using the AlgoMed algometer, which applies calibrated pressure stimuli to assess the minimum pressure at which pain is perceived. Higher thresholds indicate lower pain sensitivity. Data will be analyzed using repeated measures statistical models to detect changes over time. This multimodal assessment captures both sensory and experiential aspects of pain, providing a comprehensive profile of pain sensitivity and adaptation to the intervention.

    Time frame: From enrolment to 3 months after the intervention

16. Change in pain tolerance, assessed by AlgoMed Algometer

    Pain tolerance will be measured using the AlgoMed algometer, defined as the maximum pressure tolerated before pain becomes intolerable. Higher tolerance values indicate better pain endurance. Measurements will be taken at baseline, post-intervention, and follow-up. Data will be analyzed using repeated measures statistical models to detect changes over time. This multimodal assessment captures both sensory and experiential aspects of pain, providing a comprehensive profile of pain sensitivity and adaptation to the intervention.

    Time frame: From enrolment to 3 months after the intervention

17. Change in subjective pain intensity, assessed by Visual Analogue Scale (VAS)

    Subjective pain intensity will be rated by participants using the Visual Analogue Scale (VAS), a 100-mm horizontal line where 0 indicates "no pain" and 100 indicates "worst imaginable pain." Higher scores indicate greater pain intensity. Assessments will occur at baseline, post-intervention, and follow-up. Data will be analyzed using repeated measures statistical models to detect changes over time. This multimodal assessment captures both sensory and experiential aspects of pain, providing a comprehensive profile of pain sensitivity and adaptation to the intervention.

    Time frame: From enrolment to 3 months after the intervention

18. Change in pain characteristics, assessed by Laitinen Pain Scale

    Pain characteristics will be assessed using the Laitinen Pain Scale, which evaluates four dimensions: pain intensity, frequency, use of analgesics, and limitations in physical activity. Participants rate each dimension on a scale from 0 to 4, with higher scores indicating greater severity or frequency. The total score is the sum of these four ratings, with a maximum possible score of 16. Assessments will occur at baseline, post-intervention, and follow-up. Data will be analyzed using repeated measures statistical models to detect changes over time. This multimodal assessment captures both sensory and experiential aspects of pain, providing a comprehensive profile of pain sensitivity and adaptation to the intervention.

    Time frame: From enrolment to 3 months after the intervention

19. Change in body weight, assessed by InBody 720 Bioimpedance Analyzer

    Body weight will be measured using a bioimpedance analyzer (InBody 720). Units: Kilograms (kg)

    Time frame: From enrolment to 3 months after the intervention

20. Change in body fat percentage, assessed by InBody 720 Bioimpedance Analyzer

    Body fat percentage will be measured using the InBody 720 bioimpedance analyzer, which estimates the proportion of fat mass relative to total body weight. Measurements will be taken at baseline, post-intervention, and follow-up to evaluate changes in adiposity. Units: Percentage (%)

    Time frame: From enrolment to 3 months after the intervention

21. Change in skeletal muscle mass, assessed by InBody 720 Bioimpedance Analyzer

    Skeletal muscle mass will be measured by the InBody 720 bioimpedance analyzer, providing an estimate of the muscle tissue mass in kilograms. Measurements at baseline, post-intervention, and follow-up will assess changes in muscle composition. Units: Kilograms (kg)

    Time frame: From enrolment to 3 months after the intervention

22. Change in Body Mass Index (BMI), calculated from InBody 720 measurements

    BMI will be calculated using the participant's weight and height measured or recorded during the study. BMI reflects the body mass relative to height squared (kg/m²). Changes in BMI will be assessed at baseline, post-intervention, and follow-up. Units: kg/m²

    Time frame: From enrolment to 3 months after the intervention

23. Change in visceral fat area, assessed by InBody 720 Bioimpedance Analyzer

    Visceral fat area, representing the fat surrounding internal organs, will be estimated by the InBody 720. Measurements at baseline, post-intervention, and follow-up will be used to monitor changes. Units: cm²

    Time frame: From enrolment to 3 months after the intervention

24. Baseline Self-Reported Physical Fitness (IFIS) vs. InBody 720

    Self-reported physical fitness will be assessed at baseline using the International Fitness Scale (IFIS), a validated questionnaire measuring perceived fitness across five domains: general fitness, cardiorespiratory fitness, muscular strength, speed-agility, and flexibility. Each item is rated on a 5-point Likert scale from 1 (very poor) to 5 (very good). Higher scores indicate better perceived fitness. The total score is the mean or sum of item responses, depending on analysis strategy. Data will be collected digitally or on paper. Descriptive statistics and correlation analyses will be used to compare IFIS scores to objective measures from the InBody 720 bioimpedance analyzer, to assess alignment between subjective and objective fitness evaluations.

    Time frame: At the baseline

25. Assessed changes from baseline postural stability and balance control

    Balance and postural stability will be assessed using the BIODEX Stabilometric Platform. This device objectively measures static and dynamic balance, overall stability, and controlled mobility. Measurements will be taken at baseline, post-intervention, and follow-up to monitor changes in postural control and balance performance.

    Time frame: From enrolment to 3 months after the intervention

26. Assessed changes from baseline neuromuscular function (isokinetic dynamometry)

    Neuromuscular performance will be evaluated using the Biodex System 4 Pro, an advanced dynamometric system for assessing and training muscle function under various contraction modes. The device allows for testing in isometric, isotonic (concentric and eccentric), isokinetic (concentric and eccentric), reactive eccentric, and passive motion conditions. It provides objective data on muscle strength, endurance, and control, with full data archiving and export capabilities for statistical analysis. Measurements will be conducted at baseline, post-intervention, and follow-up to detect changes in neuromuscular function over time.

    Time frame: From enrolment to 3 months after the intervention

27. Assessed changes from baseline cardiopulmonary fitness (ergospirometry)

    Cardiopulmonary capacity will be evaluated using the Jaeger Oxycon Pro stationary ergospirometer, which analyzes exhaled gases during exercise to assess respiratory and circulatory function. The device uses precise O2 and CO2 analyzers to conduct Breath-by-Breath (3B) analysis, providing detailed functional assessments of the cardiovascular and pulmonary systems. Key parameters measured include maximum oxygen uptake (VO2 max), peak oxygen uptake (VO2 peak), ventilatory response to exercise (VE/VCO2 slope), and the respiratory exchange ratio (RER = VCO2/VO2), which is useful for evaluating anaerobic metabolism during exercise. These measurements will be taken at baseline, post-intervention, and follow-up to assess improvements in cardiorespiratory fitness.

    Time frame: From enrolment to 3 months after the intervention

28. Assessed changes from baseline lower limb power and force (vertical and horizontal jumping)

    Jumping ability and lower limb power will be assessed using the Kistler Model 9286BA dynamometric platform with MARS software. The platform, equipped with piezoelectric sensors, provides kinetic analysis of ground reaction forces during static and dynamic activities. It measures static body postural forces in a standing position, as well as dynamic forces during walking, running, and jumping. The platform captures both vertical and horizontal components of ground reaction forces during the support phase, enabling the evaluation of lower limb power, explosive strength, and maximal jump performance (e.g., vertical jump height and maximum power output). Measurements will be taken at baseline, post-intervention, and follow-up to assess changes in lower limb performance.

    Time frame: From enrolment to 3 months after the intervention

29. Assessed changes from baseline grip strength

    Grip strength will be measured using the SAEHAN electronic dynamometer with Herkules software. This device evaluates hand muscle strength by measuring grip force in an isometric test. The dynamometer features a five-level adjustable grip (ranging from 3.4 cm to 8.5 cm) to accommodate different hand sizes. The measurements will be taken at baseline, post-intervention, and follow-up to track changes in muscle strength and hand function.

    Time frame: From enrolment to 3 months after the intervention

30. Assessed changes from baseline blood lactate levels

    Blood lactate concentration will be measured using the Lactate Scout 4 system. This device is designed for assessing lactate levels in capillary blood, providing insights into changes in physical fitness and endurance. Lactate levels will be measured by finger prick during the exercise test. A baseline assessment will be performed 5-7 minutes before the start of the test, then levels will be checked during the warm-up and twice during the exercise phase. Subsequent tests will be performed 2 and 5 minutes after the end of exercise. The test will be performed before the Onco-Move training intervention and after participation in 16 weeks of training (lactate levels tested seven times during each test).

    Time frame: From enrolment to the the end of the intervention

31. Change in serum concentration of Interleukin-6 (IL-6)

    IL-6 concentration will be measured in blood samples collected at baseline, post-intervention, and follow-up to assess inflammatory response. IL-6 is a pro-inflammatory cytokine associated with exercise-induced immune modulation. Units: pg/mL

    Time frame: From enrolment to 3 months after the intervention]

32. Change in serum concentration of Interleukin-15 (IL-15)

    IL-15 will be measured to evaluate immune and metabolic responses to the intervention. This cytokine plays a role in skeletal muscle metabolism and immune signaling. Units: pg/mL

    Time frame: From enrolment to 3 months after the intervention

33. Change in serum concentration of Irisin

    Irisin levels will be assessed as a biomarker of exercise-induced metabolic activity and browning of adipose tissue. Units: ng/mL

    Time frame: From enrolment to 3 months after the intervention

34. Change in serum concentration of Brain-Derived Neurotrophic Factor (BDNF)

    BDNF will be measured to assess neuroplasticity and cognitive adaptations in response to the intervention. It is involved in neuronal survival, development, and synaptic plasticity. Units: ng/mL

    Time frame: From enrolment to 3 months after the intervention

35. Change in serum concentration of SPARC (Secreted Protein, Acidic and Rich in Cysteine)

    SPARC will be assessed to evaluate its role in exercise-induced muscle adaptation and extracellular matrix remodeling. Units: ng/mL

    Time frame: From enrolment to 3 months after the intervention

36. Change in serum concentration of Decorin

    Decorin will be analyzed as a marker of muscle regeneration and anti-fibrotic activity post-intervention. Units: ng/mL

    Time frame: From enrolment to 3 months after the intervention

37. Distribution of ACE Gene Polymorphisms

    Polymorphisms in the Angiotensin-Converting Enzyme (ACE) gene will be analyzed using blood samples to assess associations with cardiorespiratory and muscular adaptation to the intervention. Genotypes (e.g., I/I, I/D, D/D) will be reported. Unit of Measure: Proportion of participants with each genotype

    Time frame: At the baseline

38. Distribution of ACTN3 Gene Polymorphisms

    The ACTN3 polymorphism will be analyzed to explore associations with muscle strength and endurance performance. Unit of Measure: Proportion of participants with each genotype

    Time frame: At the baseline

39. Distribution of PPARGC1A Gene Polymorphisms

    Polymorphisms in the Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha (PPARGC1A) gene will be examined for associations with mitochondrial function and metabolic adaptation.

    Time frame: At the baseline

40. Distribution of BDNF Gene Polymorphisms

    The BDNF Val66Met polymorphism will be genotyped to assess its role in neuroplasticity and mood changes in response to the intervention. Unit of Measure: Proportion of Val/Val, Val/Met, and Met/Met genotypes

    Time frame: At the baseline

41. Distribution of VEGF Gene Polymorphisms

    Polymorphisms in the VEGF gene will be analyzed to explore associations with vascular adaptation. Unit of Measure: Proportion of genotype variants

    Time frame: At the baseline

42. Distribution of IL6 Gene Polymorphisms

    The IL6 polymorphisms will be assessed for its role in inflammatory response to the intervention. Unit of Measure: Proportion of G/G, G/C, and C/C genotypes

    Time frame: At the baseline

43. Distribution of NOS3 Gene Polymorphisms

    NOS3 will be evaluated in relation to endothelial function and exercise response. Unit of Measure: Proportion of G/G, G/T, and T/T genotypes

    Time frame: At the baseline

44. Distribution of HIF1A Gene Polymorphisms

    HIF1A will be assessed for potential links with hypoxia tolerance and metabolic response. Unit of Measure: Proportion of Pro/Pro, Pro/Ser, and Ser/Ser genotypes

    Time frame: At the baseline

45. Distribution of TNF-α Gene Polymorphisms

    The TNF-α will be genotyped to examine inflammatory regulation. Unit of Measure: Proportion of G/G, G/A, and A/A genotypes

    Time frame: At the baseline

46. Distribution of mTOR Pathway Gene Polymorphisms

    Selected polymorphisms in genes from the mTOR pathway will be analyzed for associations with metabolic and muscular adaptation. Unit of Measure: Proportion of genotype variants

    Time frame: At the baseline

47. Change in relative telomere length and telomerase activity

    Telomere length and telomerase activity will be measured using qPCR or ELISA-based assays to evaluate cellular aging over the course of the intervention. Unit of Measure: * Telomere length: T/S ratio * Telomerase activity: Units per µg protein

    Time frame: From enrolment to 3 months after the intervention

48. Adherence to the mediterranean diet assessed by the 14-Item MEDAS Questionnaire

    Adherence to a Mediterranean dietary pattern will be assessed using the 14-item Mediterranean Diet Adherence Screener (MEDAS), originally developed and validated in the PREDIMED trial. This questionnaire evaluates the frequency of consumption of key food components characteristic of the Mediterranean diet, such as olive oil, fruits, vegetables, legumes, nuts, fish, wine, and limits on red meat and processed foods. Each item is scored as 0 (does not meet the criterion) or 1 (meets the criterion), resulting in a total score ranging from 0 to 14, where higher scores indicate greater adherence to the Mediterranean diet. Unit of Measure: Score on a 0-14 scale

    Time frame: From Baseline up to 3 months after the intervention

Publications

• Cufer T, Kosty MP; Curriculum Development Subgroup-ESMO/ASCO Global Curriculum Working Group. ESMO/ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2023. ESMO Open. 2023 Dec;8(6):101631. doi: 10.1016/j.esmoop.2023.101631. Epub 2023 Oct 23. PubMed 38158226 ↗
• Vasilopoulou M, Asimakopoulou Z, Velissari J, Vicha A, Rizogianni M, Pusa S, Stoven S, Ficarra S, Bianco Alpha, Jimenez-Pavon D, Ponce Gonzalez Jesus G, Tavares Paula C, Gomes B, Bayer D, Silva S, Nogueira C, Papakonstantinou S, Musa K, Glorioso F, Vantarakis A. Interventions about physical activity and diet and their impact on adolescent and young adult cancer survivors: a Prisma systematic review. Support Care Cancer. 2024 May 13;32(6):342. doi: 10.1007/s00520-024-08516-0. PubMed 38739198 ↗
• Ortega-Gomez S, Di Bartolo L, Velissari J, Gomes B, Pusa S, Thaller J, Papakonstantinou S, Kirkar M, Iannitto E, Moura N, Nogueira C, Ponce-Gonzalez JG, Baxter R, Tavares P, Vantarakis A, Bianco A, Carbonell-Baeza A, Jimenez-Pavon D; OACCUs consortium. Exploring the health benefits of outdoor exercise for cancer survivors: a systematic review of more than 700 individuals. Syst Rev. 2025 May 7;14(1):101. doi: 10.1186/s13643-025-02834-y. PubMed 40336008 ↗
• Courneya KS, Vardy JL, O'Callaghan CJ, Gill S, Friedenreich CM, Wong RKS, Dhillon HM, Coyle V, Chua NS, Jonker DJ, Beale PJ, Haider K, Tang PA, Bonaventura T, Wong R, Lim HJ, Burge ME, Hubay S, Sanatani M, Campbell KL, Arthuso FZ, Turner J, Meyer RM, Brundage M, O'Brien P, Tu D, Booth CM; CHALLENGE Investigators. Structured Exercise after Adjuvant Chemotherapy for Colon Cancer. N Engl J Med. 2025 Jul 3;393(1):13-25. doi: 10.1056/NEJMoa2502760. Epub 2025 Jun 1. PubMed 40450658 ↗
• Ng AH, Ngo-Huang A, Vidal M, Reyes-Garcia A, Liu DD, Williams JL, Fu JB, Yadav R, Bruera E. Exercise Barriers and Adherence to Recommendations in Patients With Cancer. JCO Oncol Pract. 2021 Jul;17(7):e972-e981. doi: 10.1200/OP.20.00625. Epub 2021 Mar 19. PubMed 33739853 ↗
• Gunnell AS, Joyce S, Tomlin S, Taaffe DR, Cormie P, Newton RU, Joseph D, Spry N, Einarsdottir K, Galvao DA. Physical Activity and Survival among Long-term Cancer Survivor and Non-Cancer Cohorts. Front Public Health. 2017 Feb 14;5:19. doi: 10.3389/fpubh.2017.00019. eCollection 2017. PubMed 28261579 ↗
• Felser S, Behrens M, Lampe H, Henze L, Grosse-Thie C, Murua Escobar H, Rohde K, Albrecht I, Zschorlich V, Junghanss C. Motivation and preferences of cancer patients to perform physical training. Eur J Cancer Care (Engl). 2020 Jul;29(4):e13246. doi: 10.1111/ecc.13246. Epub 2020 May 31. PubMed 32476203 ↗
• Blaney JM, Lowe-Strong A, Rankin-Watt J, Campbell A, Gracey JH. Cancer survivors' exercise barriers, facilitators and preferences in the context of fatigue, quality of life and physical activity participation: a questionnaire-survey. Psychooncology. 2013 Jan;22(1):186-94. doi: 10.1002/pon.2072. Epub 2011 Oct 6. PubMed 23296635 ↗
• Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024 May-Jun;74(3):229-263. doi: 10.3322/caac.21834. Epub 2024 Apr 4. PubMed 38572751 ↗
• Miller KD, Fidler-Benaoudia M, Keegan TH, Hipp HS, Jemal A, Siegel RL. Cancer statistics for adolescents and young adults, 2020. CA Cancer J Clin. 2020 Nov;70(6):443-459. doi: 10.3322/caac.21637. Epub 2020 Sep 17. PubMed 32940362 ↗
• Campbell KL, Winters-Stone KM, Wiskemann J, May AM, Schwartz AL, Courneya KS, Zucker DS, Matthews CE, Ligibel JA, Gerber LH, Morris GS, Patel AV, Hue TF, Perna FM, Schmitz KH. Exercise Guidelines for Cancer Survivors: Consensus Statement from International Multidisciplinary Roundtable. Med Sci Sports Exerc. 2019 Nov;51(11):2375-2390. doi: 10.1249/MSS.0000000000002116. PubMed 31626055 ↗

Related links

• Recruitment website ↗

Individual participant data

Plan to share: Undecided